文献速递真菌感染细菌感染、耐药与抗菌药物

印度耳念珠菌13年临床分离株抗真菌耐药趋势及唑类耐药机制研究

Trends in Antifungal Resistance and Mechanistic Insights Into Azole Resistance in Candida (Candidozyma) auris: A 13-Year Study of a Comprehensive Set of Clinical Isolates From India.
PubMed 文献 · Clin Infect Dis · 2026-01-01

该研究分析了2009至2021年印度37家医疗中心的596株耳念珠菌临床分离株,发现80.0%对氟康唑耐药、27.9%对伏立康唑耐药,3.2%为多重耐药;ERG11突变与表达上调及外排泵参与唑类耐药,所有菌株属分支I。

要点

  • 印度耳念珠菌临床分离株对氟康唑耐药率达80.0%,伏立康唑耐药率27.9%。
  • 3.2%分离株为多重耐药,两性霉素B和卡泊芬净耐药有增加趋势。
  • ERG11的Y132F和K143R突变见于敏感与耐药株,耐药机制涉及表达上调等多途径。

核心结论

  • 印度耳念珠菌临床分离株抗真菌耐药水平高,唑类耐药涉及ERG11突变、基因表达上调及外排泵等多重机制。

研究设计与样本

  • 回顾性分析2009至2021年印度37家医疗中心收集的596株耳念珠菌临床分离株,进行抗真菌药敏试验。
  • 对45株代表性分离株测序ERG11基因,对20株在氟康唑压力下用qRT-PCR评估ERG11、MDR1和CDR1表达并检测细胞壁麦角固醇含量。
  • 对235株分离株进行短串联重复序列(STR)基因分型。

主要发现

  • 50.1%的分离株来自印度北部,27.6%来自东部,13.6%来自南部,多数来自私立医院。
  • 80.0%的分离株对氟康唑耐药,27.9%对伏立康唑耐药,3.2%为多重耐药。
  • ERG11的Y132F和K143R突变在氟康唑敏感和耐药分离株中均存在。
  • 50%的氟康唑敏感分离株在氟康唑处理后显示ERG11表达和麦角固醇含量升高,且敏感株基础细胞壁麦角固醇更高。
  • 全部分离株经STR分型均属于分支I。

临床怎么用

  • 印度耳念珠菌临床分离株对氟康唑耐药率极高,经验性用药需参考本地药敏数据。
  • 对耳念珠菌感染应进行药敏试验,关注多重耐药株及两性霉素B、卡泊芬净耐药增加趋势。
  • 唑类耐药机制复杂,ERG11突变不能单独预测耐药,需综合评估表达调控和外排泵等因素。

局限性

  • ERG11测序仅针对45株代表性分离株,表达分析仅20株,机制结论外推需谨慎。
  • 研究仅纳入印度分离株,结论推广至其他地区需进一步验证。
  • 原文未报告其他可能耐药机制(如应激反应通路)的实验数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The objective of the study was to elucidate antifungal resistance and associated azole resistance mechanisms in Candida (Candidozyma) auris isolates across India over a period of 13 years (2009-2021). METHODS: A total of 596 C. auris isolates from 37 healthcare centers were collected. Antifungal susceptibility was performed and ERG11 gene was sequenced for 45 representative isolates. The ERG11 and efflux pump (MDR1 and CDR1) expression under fluconazole drug pressure was assessed by quantitative reverse-transcription polymerase chain reaction (n = 20) along with cell wall ergosterol content estimation. Short tandem repeat (STR) genotyping was done on 235 isolates. RESULTS: The highest number of isolates (50.1%) was recovered from northern India, followed by eastern (27.6%) and southern India (13.6%). The majority of the isolates were recovered from private sector hospitals. A total of 80.0% and 27.9% of isolates were resistant to fluconazole and voriconazole, respectively. A notable increase in resistance to amphotericin B and caspofungin was observed, with 3.2% of isolates being multidrug resistant. In ERG11, Y132F and K143R mutations were present in both fluconazole-susceptible and -resistant isolates; in addition, 50% of fluconazole-susceptible isolates showed elevated ERG11 expression and ergosterol content upon fluconazole treatment. Basal level cell wall ergosterol was higher in fluconazole-susceptible isolates. All isolates belonged to clade I with STR genotyping. CONCLUSIONS: Our study demonstrates high levels of antifungal resistance in the largest collection of Indian C. auris clinical isolates reported to date. Besides mutations and gene expressions, other pathways conferring drug resistance, such as stress response, must be studied to further understand the evolution of this pathogen.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Das S, Singh S, Tawde Y, et al. Trends in Antifungal Resistance and Mechanistic Insights Into Azole Resistance in Candida (Candidozyma) auris: A 13-Year Study of a Comprehensive Set of Clinical Isolates From India. Clin Infect Dis. 2026. PMID: 42059109. doi:10.1093/cid/ciag257

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。